Literature DB >> 12686092

The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines.

Kristin L Nichol1.   

Abstract

Influenza is a major cause of morbidity and mortality worldwide. Currently available inactivated influenza virus vaccines are safe and effective in preventing influenza. Substantial health benefits are seen across all age and risk groups. Studies assessing the economic benefits of vaccination suggest that vaccination is highly cost effective and in many cases cost saving among the elderly. Influenza vaccination has also been associated with significant economic benefits in younger adults and children. Additional health economic studies from developing countries and from tropical/subtropical regions will be vitally important for better understanding of the global burden of influenza and potential benefits of vaccination.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12686092     DOI: 10.1016/s0264-410x(03)00070-7

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  72 in total

1.  Live attenuated influenza virus expressing human interleukin-2 reveals increased immunogenic potential in young and aged hosts.

Authors:  Boris Ferko; Christian Kittel; Julia Romanova; Sabine Sereinig; Hermann Katinger; Andrej Egorov
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

2.  Influenza vaccination: policy versus evidence: no gap between policy and evidence.

Authors:  David S Fedson; Kristin L Nichol
Journal:  BMJ       Date:  2006-11-11

3.  The effectiveness of vaccine day and educational interventions on influenza vaccine coverage among health care workers at long-term care facilities.

Authors:  Akiko C Kimura; Christine N Nguyen; Jeffrey I Higa; Eric L Hurwitz; Duc J Vugia
Journal:  Am J Public Health       Date:  2007-02-28       Impact factor: 9.308

4.  [Vaccination against pneumococci and influenza. How good is the evidence?].

Authors:  B Babouee; A F Widmer; M Battegay
Journal:  Internist (Berl)       Date:  2011-03       Impact factor: 0.743

5.  Non-traditional settings for influenza vaccination of adults: costs and cost effectiveness.

Authors:  Lisa A Prosser; Megan A O'Brien; Noelle-Angelique M Molinari; Katherine H Hohman; Kristin L Nichol; Mark L Messonnier; Tracy A Lieu
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

6.  [Influenza: special aspects in old age].

Authors:  A Kwetkat; A Leischker; H J Heppner
Journal:  Z Gerontol Geriatr       Date:  2018-06-27       Impact factor: 1.281

7.  Extending the cytoplasmic tail of the influenza a virus M2 protein leads to reduced virus replication in vivo but not in vitro.

Authors:  Wai-Hong Wu; Andrew Pekosz
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

8.  Influenza vaccination in the elderly: seeking new correlates of protection and improved vaccines.

Authors:  Janet E McElhaney
Journal:  Aging health       Date:  2008-12-01

9.  Practice and physician characteristics associated with influenza vaccination delivery rates following a patient reminder letter intervention.

Authors:  Kelly K Anderson; Rolf J Sebaldt; Lynne Lohfeld; Ron Goeree; Faith C Donald; Ken Burgess; Janusz Kaczorowski
Journal:  J Prim Prev       Date:  2008-01-19

10.  Rituximab-treated patients have a poor response to influenza vaccination.

Authors:  Robert A Eisenberg; Abbas F Jawad; Jean Boyer; Kelly Maurer; Kenyetta McDonald; Eline T Luning Prak; Kathleen E Sullivan
Journal:  J Clin Immunol       Date:  2012-10-14       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.